Zobrazeno 1 - 10
of 16
pro vyhledávání: '"James Dunyak"'
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 3, Pp 143-152 (2020)
Differences in the effect of gefitinib and chemotherapy on tumor burden in non‐small cell lung cancer remain to be fully understood. Using a Bayesian hierarchical model of tumor size dynamics, we estimated the rates of tumor growth and treatment re
Externí odkaz:
https://doaj.org/article/edabaaf5538348a88ecb98bf8cc7d5fb
Autor:
Fred Saad, Philip Kantoff, Jonathan I. Epstein, Mathieu Latour, Cristina Magi-Galluzzi, Eric A. Klein, Massimo Loda, James Dunyak, Julie Nardone, Eldar Giladi, Hua Chang, Alex Kaprelyants, Aeron Hurley, Christina Ernst, Louis Coupal, Teresa Capela, Sibgat Choudhury, Clayton Small, Thomas P. Nifong, Mathew Putzi, Michail Shipitsin, David L. Rimm, David M. Berman, Peter Blume-Jensen
Purpose: Prostate cancer aggressiveness and appropriate therapy are routinely determined following biopsy sampling. Current clinical and pathologic parameters are insufficient for accurate risk prediction leading primarily to overtreatment and also m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8a1d5ad71950008144484ceac754a37
https://doi.org/10.1158/1078-0432.c.6524298
https://doi.org/10.1158/1078-0432.c.6524298
Autor:
Fred Saad, Philip Kantoff, Jonathan I. Epstein, Mathieu Latour, Cristina Magi-Galluzzi, Eric A. Klein, Massimo Loda, James Dunyak, Julie Nardone, Eldar Giladi, Hua Chang, Alex Kaprelyants, Aeron Hurley, Christina Ernst, Louis Coupal, Teresa Capela, Sibgat Choudhury, Clayton Small, Thomas P. Nifong, Mathew Putzi, Michail Shipitsin, David L. Rimm, David M. Berman, Peter Blume-Jensen
Supplementary Methods, Table S1, Figures S1-7. Methods for quantitative multiplex proteomics imaging (QMPI) Clinical studies: Statistical plan Table S1. Clinical Validation Study. Comparison of Predictive Value of the 8-Biomarker Assay for Favorable
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a775876007c847964815ceef0082305
https://doi.org/10.1158/1078-0432.22459749
https://doi.org/10.1158/1078-0432.22459749
Autor:
Sergey Gavrilov, Sergey Aksenov, Gabriel Helmlinger, James Dunyak, Kirill Peskov, Kirill Zhudenkov
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
Therapy optimization remains an important challenge in the treatment of advanced non-small cell lung cancer (NSCLC). We investigated tumor size (sum of the longest diameters (SLD) of target lesions) and neutrophil-to-lymphocyte ratio (NLR) as longitu
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology
CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 3, Pp 143-152 (2020)
CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 3, Pp 143-152 (2020)
Differences in the effect of gefitinib and chemotherapy on tumor burden in non‐small cell lung cancer remain to be fully understood. Using a Bayesian hierarchical model of tumor size dynamics, we estimated the rates of tumor growth and treatment re
Autor:
Mario Nagase, Mitsuo Higashimori, Shinya Ueda, Katsuomi Ichikawa, Nidal Al-Huniti, James Dunyak
Publikováno v:
Pharmaceutical Statistics. 19:22-30
As described in the ICH E5 guidelines, a bridging study is an additional study executed in a new geographical region or subpopulation to link or "build a bridge" from global clinical trial outcomes to the new region. The regulatory and scientific goa
Autor:
Ana I. Kuehne, Katie Streicher, Richard Roque, Yueh-Ming Loo, Jerome Bouquet, Daniel J Flores, Robert A. Gasser, Michael E Abram, Nicholas J. Bond, Andrew S. Herbert, Mark T. Esser, John M. Dye, Elizabeth J. Kelly, Rosalinda H Arends, Kim Rosenthal, Nicole L. Kallewaard, Owen Cornwell, Kevin M Tuffy, Hanne Andersen, Yue Huang, James E. Crowe, Helen Bright, Anastasia Aksyuk, Menelas N. Pangalos, Robert H. Carnahan, Patrick M. McTamney, James Dunyak, Seme Diallo, Kuishu Ren, Anton I. Rosenbaum, Lily Cheng
Despite the success of SARS-CoV-2 vaccines, there remains a need for more prevention and treatment options for individuals remaining at risk of COVID-19. Monoclonal antibodies (mAbs) against the viral spike protein have potential to both prevent and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e9a7012b82f9d3d04b1fca881d83af33
https://doi.org/10.1101/2021.08.30.21262666
https://doi.org/10.1101/2021.08.30.21262666
Autor:
Ryan J. Hartmaier, Martin Johnson, Helen Tomkinson, Ganesh Mugundu, James Dunyak, Aleksandra Markovets, Juliann Chmielecki, Karthick Vishwanathan, Carl Barrett, Philip Overend
Publikováno v:
Cancer Research. 80:CT024-CT024
Circulating tumor DNA is released into the bloodstream from tumors and can reflect both intra-tumor heterogeneity and clonal evolution.1 As ctDNA levels are thought to reflect tumor burden, a decrease in ctDNA while on therapy may suggest treatment e
Autor:
Gabriel Helmlinger, Nidal Al-Huniti, Patrick D. Mitchell, Bengt Hamrén, Donald R. Stanski, James Dunyak, James Matcham
Publikováno v:
Pharmaceutical statistics. 17(2)
Model-informed drug discovery and development offers the promise of more efficient clinical development, with increased productivity and reduced cost through scientific decision making and risk management. Go/no-go development decisions in the pharma
Publikováno v:
Cancer Research. 79:1674-1674
Objectives: Dynamics of tumor size have long been used for the clinical diagnosis, staging, prognosis and treatment of non-small cell lung cancer (NSCLC). The aim of this work was to develop a joint statistical framework to interrogate the longitudin